Savara (SVRA) Non-Current Deferred Tax Liability (2011 - 2018)
Savara (SVRA) reported Non-Current Deferred Tax Liability of $2.5 million for Q3 2018, down 77.5% year-over-year from $11.3 million in Q3 2017, and down 0.78% on a QoQ basis from $2.6 million in Q2 2018.
Savara (SVRA) has 8 years of Non-Current Deferred Tax Liability data on file, last reported at $2.5 million in Q3 2018.
- Quarterly Non-Current Deferred Tax Liability fell 77.5% year-over-year to $2.5 million in Q3 2018, while the trailing twelve-month figure through Sep 2018 was $2.5 million (down 77.5% YoY) and the FY2017 annual result came in at $7.2 million, up 211.54% from the prior year.
- Non-Current Deferred Tax Liability retreated to $2.5 million in Q3 2018 per SVRA's latest filing, from $2.6 million in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $11.3 million in Q3 2017 and bottomed at $995000.0 in Q1 2017.
- The 5-year median for Non-Current Deferred Tax Liability is $3.4 million (2014), against an average of $4.1 million.
- The widest annual swing landed in 2017, when Non-Current Deferred Tax Liability surged 230.88%; it then plunged 77.5% in 2018.
- Tracing SVRA's Non-Current Deferred Tax Liability over 5 years: stood at $3.4 million in 2014, then changed by 0.0% to $3.4 million in 2015, then sank by 32.29% to $2.3 million in 2016, then soared by 211.54% to $7.2 million in 2017, then tumbled by 64.71% to $2.5 million in 2018.
- Per Business Quant, the three latest SVRA Non-Current Deferred Tax Liability figures stand at $2.5 million (Q3 2018), $2.6 million (Q2 2018), and $2.7 million (Q1 2018).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Savara | 1.30 Bn | 1.30 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2018 | 2.53 Mn |
| Sep 30, 2018 | 2.53 Mn |
| Jun 30, 2018 | 2.55 Mn |
| Jun 30, 2018 | 2.55 Mn |
| Mar 31, 2018 | 2.69 Mn |
| Mar 31, 2018 | 2.69 Mn |
| Dec 31, 2017 | 7.18 Mn |
| Dec 31, 2017 | 7.18 Mn |
| Sep 30, 2017 | 11.26 Mn |
| Sep 30, 2017 | 11.26 Mn |
| Jun 30, 2017 | 11.18 Mn |
| Jun 30, 2017 | 11.18 Mn |
| Mar 31, 2017 | 995,000.00 |
| Mar 31, 2017 | 995,000.00 |
| Dec 31, 2016 | 2.31 Mn |
| Dec 31, 2016 | 2.31 Mn |
| Sep 30, 2016 | 3.40 Mn |
| Sep 30, 2016 | 3.40 Mn |
| Jun 30, 2016 | 3.40 Mn |
| Jun 30, 2016 | 3.40 Mn |
| Mar 31, 2016 | 3.40 Mn |
| Mar 31, 2016 | 3.40 Mn |
| Dec 31, 2015 | 3.40 Mn |
| Dec 31, 2015 | 3.40 Mn |
| Sep 30, 2015 | 3.40 Mn |
| Sep 30, 2015 | 3.40 Mn |
| Jun 30, 2015 | 3.40 Mn |
| Jun 30, 2015 | 3.40 Mn |
| Mar 31, 2015 | 3.40 Mn |
| Mar 31, 2015 | 3.40 Mn |
| Dec 31, 2014 | 3.40 Mn |
| Dec 31, 2014 | 3.40 Mn |
| Sep 30, 2014 | 3.40 Mn |
| Sep 30, 2014 | 3.40 Mn |
| Jun 30, 2014 | 3.40 Mn |
| Jun 30, 2014 | 3.40 Mn |
| Mar 31, 2014 | 3.40 Mn |
| Mar 31, 2014 | 3.40 Mn |
| Dec 31, 2013 | 2.61 Mn |
| Dec 31, 2013 | 2.61 Mn |
| Sep 30, 2013 | 2.61 Mn |
| Sep 30, 2013 | 2.61 Mn |
| Jun 30, 2013 | 2.61 Mn |
| Jun 30, 2013 | 2.61 Mn |
| Mar 31, 2013 | 2.61 Mn |
| Mar 31, 2013 | 2.61 Mn |
| Dec 31, 2012 | 2.61 Mn |
| Dec 31, 2012 | 2.61 Mn |
| Sep 30, 2012 | 2.61 Mn |
| Sep 30, 2012 | 2.61 Mn |
| Jun 30, 2012 | 2.61 Mn |
| Jun 30, 2012 | 2.61 Mn |
| Mar 31, 2012 | 2.61 Mn |
| Mar 31, 2012 | 2.61 Mn |
| Dec 31, 2011 | 2.61 Mn |
| Dec 31, 2011 | 2.61 Mn |